A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults
← catalyst calendarSponsored by Ipsen (industry) · IPN.PA — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Double · Prevention
Enrollment
751actual
Sites
105
Countries
Canada, Czechia, France +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-09-29 | actual | When the study began enrolling |
| Primary completion | 2026-06-01 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-11-06 | estimated | The whole study's end, after follow-up |
| First posted | 2023-09-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-16 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Episodic Migraine
Interventions
- Biological: Botulinum toxin type A — also filed as Dysport®
- Biological: Botulinum toxin type A — also filed as Dysport®
- Other: Placebo
- Biological: Botulinum toxin type A — also filed as Dysport®
- Biological: Botulinum toxin type A — also filed as Dysport®
Primary outcome
what the primary-completion date above is the date OFChange from baseline in monthly migraine days (MMD)
measured Every 4 weeks from Week 4 (Weeks 1-4) to Week 24 (Weeks 21-24)
Permalink · IPN.PA's whole pipeline · Catalyst calendar · Every registered study · What changed